Key clinical point: Ofatumumab has superior efficacy in relapsing-remitting MS, compared with teriflunomide.
Major finding: Compared with teriflunomide, ofatumumab reduced annualized relapse rate by more than 50%.
Study details: Two contemporaneous phase 3 studies that included a total of 1,882 patients with relapsing-remitting MS.
Disclosures: Novartis Pharma funded the research. Dr. Hauser has received travel reimbursement from F. Hoffmann-La Roche and Novartis for meetings and presentations related to anti-CD20 therapies.